Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ergoloid Mesylates and 5-HTP in Adult Males With Fragile X Syndrome
NCT05030129Phase 2Completed
- Start
- Oct 2021
- Primary completion
- Jan 2023
- Modality
- Peptides, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ergoloid mesylates, 5-hydroxytryptophan in Fragile X syndrome (FXS). Started Oct 2021; status: completed.
02
Drugs
ergoloid mesylates5-hydroxytryptophan
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT05030129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030129.